Eight years' experience of an extended-interval dosing protocol for gentamicin in neonates

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 1043-1049

  Begg, Evan J ^a   Vella Brincat, Jane W A ^a   Robertshawe, Barbara ^a   Mcmurtrie, Mark J ^b   Kirkpatrick, Carl M J ^b   Darlow, Brian ^c  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

^b UNIVERSITY OF QUEENSLAND   (Australia)

^c CHRISTCHURCH WOMEN S HOSPITAL   (New Zealand)

Author keywords

Aminoglycosides; Pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

GENTAMICIN;

AREA UNDER THE CURVE; ARTICLE; BIRTH WEIGHT; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG HALF LIFE; HUMAN; MAJOR CLINICAL STUDY; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MAXIMUM PLASMA CONCENTRATION; NEWBORN; NEWBORN CARE; SINGLE DRUG DOSE;

ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; GENTAMICINS; HALF-LIFE; HUMANS; INFANT, NEWBORN; METABOLIC CLEARANCE RATE; MODELS, THEORETICAL; PLASMA; TISSUE DISTRIBUTION;

EID: 64649097403     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp073     Document Type: Article

References (12)

1. Stickland MD, Kirkpatrick CMJ, Begg EJ et al. An extended dosing method for gentamicin in neonates. J Antimicrob Chemother 2001; 48: 887-93.
2. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
3. Barclay ML, Begg EJ. Aminoglycoside adaptive resistance: Importance for effective dosage regimens. Drugs 2001; 61: 713-21.
4. Begg EJ, Barclay ML, Duffull SB. A suggested approach to once daily aminoglycoside dosing. Br J Clin Pharmacol 1995; 39: 605-9.
5. Kirkpatrick CMJ, Duffull SB, Begg EJ. Pharmacokinetics of gentamicin in 957 patients with varying renal function dosed once daily. J Clin Pharmacol 1999; 47: 637-43.
6. Rao SC, Ahmed A, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates (review). Cochrane Database Syst Rev 2006; issue 1: CD005091.
7. Hayani KC, Hatzopoulos FK, Frank AL et al. Pharmacokinetics of once daily gentamicin in neonates. J Pediatr 1996; 131: 76-80.
8. Stolk LML, Degraeuwe PLJ, Neiman FHM et al. Population pharmacokinetics and relationship between demographic and clinical variables and pharmacokinetics of gentamicin in neonates. Ther Drug Monit 2002; 24: 527-31.
9. Lingvall M, Reith D, Broadbent R. The effect of sepsis upon gentamicin pharmacokinetics in neonates. Br J Clin Pharmacol 2005; 59: 54-61.
10. Murphy JE. Prediction of gentamicin peak and trough concentrations from six extended-interval dosing protocols for neonates. Am J Health Syst Pharm 2005; 62: 823-7.
11. Veltkamp SA, Westerman EM, Srij AJ et al. Gentamicin in preterm neonates: An extended interval dosing schedule. Eur J Hosp Pharm 2007; 13: 92-7.
12. Izquierdo M, Lanao JM, Cervero L et al. Population pharmacokinetics of gentamicin in premature infants. Ther Drug Monit 1992; 14: 177-83.